# Biomed-Lublin signs distribution deal with Bioton for Distreptaza in Poland

Biomed-Lublin signed a cooperation agreement with Bioton for the sale and distribution of Distreptaza in Poland until end of 2022, with a total estimated value of about 45 million PLN. Biomed will also launch a new Distreptaza production line in Q3 2018, doubling capacity.

- Type: Contract
- Announced: 2018-02-12
- Where: Poland
- Value: $13.0M (45.0M PLN)
- Status: announced
- Capacity: doubled production capacity
- Products: Distreptaza (suppository drug)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Biomed-Lublin](https://endata.com/companies/30018.md) (supplier)
- [Bioton](https://endata.com/companies/30019.md) (customer)

## Sources

- [bankier.pl](https://www.bankier.pl/wiadomosc/Biomed-Lublin-bedzie-wspolpracowal-z-Biotonem-przy-sprzedazy-i-dystrybucji-Distreptazy-7571989.html), 2018-02-12: "Zainwestowaliśmy w uruchomienie nowego wydziału Distreptazy, co umożliwi nam podwojenie jej produkcji oraz obniży koszty jej wytwarzania."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.